|
Dr. Lonky is
board certified in internal medicine,
pulmonary and critical care medicine.
As a National Institutes of Health post
doctoral fellow and as a full-time faculty
member at the University of California,
San Diego he spearheaded a research
team studying the cellular and biochemical
mechanisms of lung injury. His practice
involves the evaluation and treatment
of patients with toxic exposures as
well as patients with lung disease.
In addition, he has served as the Chief
Medical Officer for a diagnostic device
company that developed technologies
for the early diagnosis of certain epithelial
cancers. His practice is located in
Los Angeles, California. |
|
|
|
Mr. Deitsch,
Chief Executive Officer of Nutra Pharma
Corp. (nutrapharma.com), served as the
President of NDA Consulting Inc., a
biotechnology research group that provided
consulting services to the pharmaceutical
industry. NDA Consulting specialized
in the research of peptides derived
from Cone Snail venom, Cobra venom and
Gila Monster venom. Mr. Deitsch holds
both a B.S. in Chemistry and an M.S.
in Biochemistry from Florida Atlantic
University and has conducted research
for the Duke University Medical School
Comprehensive Cancer Center. Mr. Deitsch
is an adjunct professor and teaches
several courses for Florida Atlantic
University's College of Business and
Continuing Education Department. |
|
|
|
|
|